Biohaven Ltd. (BHVN) stock rose 24.39% over two sessions, from the close on Oct. 20, 2026 to the latest quote on Oct. 22, 2026, and gained 25.02% on Oct. 22 alone. According to Barron's, the move came after the Food and Drug Administration (FDA) agreed to review a New Drug Application for Vyglxia, Biohaven's experimental treatment for spinocerebellar ataxia. Biohaven reported $0.00 in revenue in each of the last five quarters, so news from the regulator matters for how investors see its outlook.
Key facts
- Oct. 22, 2026: BHVN traded at 14.69 USD as of the latest quote on Oct. 22, up 25.02% on the day. Barron's said the stock was heading for an unusually strong day. The 52-week range is 7.48-18.57 USD.
- Oct. 20-22, 2026: The two-session gain was 24.39%.
- Oct. 22, 2026: Benzinga reported that the FDA set a review date for the rare-disease drug.
- Q2 FY2026 (quarter ended June 30, 2026): Revenue was $0.00 and net income was $-137.3M. Diluted EPS (earnings per share) was -0.91, against an analyst estimate of -0.76098.
- Nov. 9, 2026: Next earnings date. FMP lists an EPS estimate of -0.60951.
- Market cap: $2.22B.
What happened
Biohaven is a biotech that develops drugs. It reported $0.00 in revenue in each of the last five quarters. Its experimental treatment, Vyglxia, targets spinocerebellar ataxia, a rare inherited condition that damages coordination and movement.
The cause of the jump comes from news coverage. Barron's reported on Oct. 22, 2026 that the FDA agreed to review the New Drug Application (NDA) for Vyglxia again. An NDA is the formal request a company files to win approval to sell a medicine in the US. Benzinga reported earlier that day that Biohaven rebounded after getting an FDA review date for the rare-disease drug. Barron's described the FDA as agreeing to review the drug "again," but the sources we reviewed give no detail on any earlier review.
Even after the gain, the latest quote of 14.69 USD is below the 52-week high of 18.57 USD.
This article relies on the Barron's and Benzinga reports. We have not seen a full FDA decision or the detailed terms of the review, so we do not describe what the FDA will conclude.
Why it matters for investors
The business today. Biohaven reported no revenue in the second quarter ended June 30, 2026, and none in the year-ago quarter. Its net loss in that quarter was $-137.3M, which FMP says is a 30.7% improvement on the year-ago quarter. Diluted EPS of -0.91 was weaker than the analyst estimate of -0.76098, a miss of $0.15 per share. The Nov. 9 report will be measured against FMP's EPS estimate of -0.60951 and its revenue estimate of $70.0M.
Five-quarter trend. Net income by quarter ran $-198.1M (Q2 FY2025), $-173.4M (Q3 FY2025), $-145.6M (Q4 FY2025), $-130.5M (Q1 FY2026) and $-137.3M (Q2 FY2026). The loss shrank for three quarters, then edged up in the latest one. Margins cannot be calculated because there is no revenue.
Cash burn eased more clearly. Operating cash flow, the cash a business uses or generates from operations, was $-145.7M in Q3 FY2025, $-130.7M in Q4 FY2025, $-149.9M in Q1 FY2026 and $-85.1M in Q2 FY2026. The latest quarter used the least cash of those four. Biohaven has paid no dividends and made no buybacks in any of these quarters.
Balance sheet. As of June 30, 2026, Biohaven held $267.9M in cash and short-term investments against $297.0M of total debt. FMP lists net debt of $59.0M. Shareholders' equity was $12.2M, so the cushion is thin. Debt/equity is 24.30. FMP's financial strength scores are weak: Piotroski 2 on a 0-9 scale and Altman Z -10.37. (Piotroski measures financial health, and Altman Z estimates bankruptcy risk. Lower is worse for both.)
Peers. Valuation ratios do not work well for a company with no profits. Biohaven's trailing P/E (price relative to earnings) is -3.17, and EV/EBITDA is -3.96. Among similar-sized biotechs, Celldex Therapeutics (CLDX; market cap $2.27B) has a P/E of -6.64, and Immunome (IMNM; market cap $2.15B) has a P/E of -7.19. AbCellera Biologics (ABCL; market cap $3.68B) has a P/E of -21.06, and Immunocore (IMCR; market cap $1.62B) has a P/E of -178.15. Negative P/Es across the group point to companies valued on future prospects rather than current profits, though Immunocore's net margin of -2.3% implies it has meaningful revenue.
Analysts. Of 25 analyst ratings, 16 are buy, 8 are hold and 1 is sell, for a consensus of "Buy." The average price target is 24.67 USD and the median is 20.00 USD. The range runs from a low of 11.00 USD to a high of 48.00 USD. The average and median targets are above the current 14.69 USD price, though analysts' estimates are opinions and can change quickly after regulatory news. FMP's own discounted cash flow model, which values a company from projected cash flows, gives -0.60 USD per share, reflecting current losses rather than future drug sales.
Our MoonshotScore. Stock Expert AI's MoonshotScore V2 for BHVN is 20.4, rated Weak. The pillars, measured against its sector, are growth 33, momentum 51, quality 23, safety 5 and valuation 18. Momentum is the strongest pillar, which fits the recent price jump. Safety is the weakest, in line with the thin equity and heavy debt. The score describes current financial data, not the odds that the FDA approves the drug.
What could go wrong
- An FDA review is not an approval. According to Barron's, the FDA agreed to review the application. That is a step forward, but the outcome of the review is separate.
- Funding. The company is burning cash and has net debt. If approval or launch is delayed, it may need to raise money or take on more debt.
- Thin balance sheet. Equity of $12.2M leaves little room for setbacks.
- Volatility. The 52-week range is wide, and a one-day jump of 25.02% can reverse on news just as quickly.
- Insiders. In the last 90 days of the filings we reviewed, there were no open-market insider purchases and no sales.
What to watch next
- Nov. 9, 2026 earnings. FMP lists an EPS estimate of -0.60951 and a revenue estimate of $70.0M. That revenue estimate looks out of line with a company that has reported no revenue, so check what management says about timing. Analysts' longer-range consensus shows no revenue for the period ending March 30, 2028, and $2.9M for the period ending June 30, 2028.
- FDA timeline. Look for the company's own statement of the review date and what the agency asked for.
- Cash use. See whether quarterly operating cash flow stays near the latest $-85.1M or returns to the higher burn of earlier quarters.
- Financing. Watch for any share sale or debt deal after the rally.
Frequently asked questions
Q: Why did Biohaven stock go up on Oct. 22, 2026?
According to Barron's, the FDA agreed to review a New Drug Application for Vyglxia, Biohaven's experimental spinocerebellar ataxia treatment. Benzinga reported that the FDA gave a review date for the rare-disease drug. The stock rose 25.02% that day to 14.69 USD as of the latest quote.Q: Does the FDA review mean Vyglxia will be approved?
No. Per Barron's, the FDA agreed to review the application, which is a step in the process and not a decision. Whether the drug is approved depends on the FDA's review.Q: Is Biohaven profitable?
No. In the second quarter ended June 30, 2026, Biohaven reported $0.00 in revenue and a net income of $-137.3M, with diluted EPS of -0.91. The loss was smaller than in the year-ago quarter, but the company reported no revenue in any of the last five quarters. As of June 30, 2026, it held $267.9M in cash and short-term investments against $297.0M of total debt.This is educational content, not investment advice. Past performance does not guarantee future results.